Specify a stock or a cryptocurrency in the search bar to get a summary
Destiny Pharma PLC
D89Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom. Address: Sussex Innovation Centre, Brighton, United Kingdom, BN1 9SB
Analytics
WallStreet Target Price
3 485.29 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures D89
Dividend Analytics D89
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History D89
Stock Valuation D89
Financials D89
Results | 2019 | Dynamics |